Johnson & Johnson unit's Janssen Pharmaceuticals acquired exclusive, global rights to Arrowhead Pharmaceuticals' hepatitis B virus candidate ARO-HBV and options to exclusively license up to three programs identified against targets selected by Janssen using the Targeted RNA interference Molecule platform from Arrowhead. The deal gives Arrowhead $175 million up front plus tiered royalties, a $75 million equity investment from J&J Innovation and about $1.6 billion in milestones related to a midstage study and three optioned programs.
Janssen acquires rights to Arrowhead's HBV candidate
Sign up for AIChE SmartBrief
News for chemical engineers
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.